Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to understand the nature of the study.~2. Obtain signed informed consent form approved by the Ethics Committee of the hospital (CEIC).~3. Male and female, ≥ 18 years at the time of the informed consent signature.~4. Patients with compensated heart failure, grade II or III as defined by the European Society of Cardiology, with a duration of ≥ 3 months at the time of inclusion documented in the patient's record or patients who previously required diuretic therapy.~5. Patients with stable heart failure on drug therapy. Stable drug therapy is defined as not having introduced any new drug for heart failure within 4 weeks prior to inclusion. Drugs doses could be adjusted during the study with the exception of the diuretics~6. Lab analysis results, vital signs and ECG within normal ranges or not considered clinically significant by the investigator.~7. For women only, the patient must be:~   * postmenopausal (≥ 1 year) or sterilized or,~  * without risk of becoming pregnant, not lactating, have a negative pregnancy test at study entry and without intention of becoming pregnant during the study course and use effective contraception.~   Postmenopausal status is defined as 12 consecutive months of spontaneous amenorrhea or confirmed by the results of follicle stimulating hormone (FSH) \> 40 mlU/mL or at least 6 months after oophorectomy (with or without hysterectomy) documented in the patients record.~8. Body weight within the normal ranges (Quetelet's index between 19 and 30) expressed as weight (kg) /height (m2).~Exclusion Criteria:~1. Hospitalization due to heart failure, acute coronary syndrome, myocardial infarction, cardiac catheterization, revascularization, cardiac arrhythmia, transient ischemic attack or stroke, cardiac arrhythmia within 6 weeks prior to inclusion or major surgery including cardiac thoracic or within 8 weeks prior to inclusion.~2. Symptoms of angina at rest or with minimal activity (class III or IV, Canadian Cardiovascular Society).~3. Severe aortic or mitral stenosis or clinically significant valvular heart disease that can lead to surgery within 12 months after inclusion.~4. Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis or clinically significant congenital heart disease.~5. If ventricular assist devices, continuous inotropic therapy or hospitalization is considered necessary in case of refractory end-stage heart failure.~6. Implementation of CRT within 3 months or cardioverter defibrillator in the 4 weeks before inclusion.~7. High probability of receiving a heart transplant within 6 months after inclusion.~8. Main organ transplant (ex. lungs, liver, kidney, heart, bone).~9. Positive surface antigen of hepatitis B, hepatitis C or HIV or a known diagnosis of AIDS.~10. Medical history or evidence of drug or alcohol abuse in the 3 months prior to inclusion.~11. Concomitant cardiovascular disease that is expected to reduce life expectancy to less than one year.~12. Scheduled routine iv infusions for heart failure (ex. inotropes, vasodilators, diuretics) or routine ultrafiltration.~13. Digoxin therapy at steady state (approximately 6 hours post-dose) exceeding 1.0 ng/mL at inclusion.~14. Chronic therapy with antiarrhythmic, antiepileptic drugs, eplerenone and espironolactone except amiodarone and beta-blockers.~15. Current intake or within 14 days prior to inclusion of a potent inhibitor of CYP2C9~16. Current intake or within 28 days prior to inclusion of a potent inducer of CYP2C9.~17. Participation, in the 60 days or 5 half lives preceding the inclusion in the study, in other clinical trial.~18. Systolic blood pressure \> 150mm Hg diastolic blood pressure \> 95 mmHg, confirmed on 2 separate visits before inclusion.~19. Heart rate in supine \> 100 beats/min after 5 minute rest or untreated symptomatic bradycardia within one month prior to inclusion.~20. Total bilirubin \> 1.5 times ULN, or ALT or AST \> 3 times ULN.~21. Estimated GFR \> 30 ml/min/1.73 m2 calculated by the modification of diet in renal disease (RD).~22. Chronic treatment with NSAIDs (\> 7 days), except aspirin \< 325 mg dose.~23. Uncontrolled insulin-dependent diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Torasemide PR 10 mg (Type: EXPERIMENTAL): None
- Furosemide-IR 40 mg (Type: ACTIVE_COMPARATOR): None
- Torasemide-IR 10 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).